Shots:

• Gates Foundation to fund $55M which may extend up to $100M for the development of preclinical vaccine and immunotherapy candidates preventing HIV and tuberculosis infection. BioNTech will retain rights to commercialize candidates in developed countries while providing affordable access to the candidates in developing countries
• The agreements will further expand the BioNTech’s infectious disease portfolio with the initiation of three new additional programs to be developed utilizing BioNTech’s mRNA platforms
• BioNTech’s infectious diseases candidates contain modified mRNA-encoding antigens specific to a target pathogen- thus resulting in activation of T cells & B cells for fighting against pathogen

Click here to­ read full press release/ article | Ref: BioNTech | Image: : BioNTech